References

Ali, N. (2020) 'Elevated level of c-reactive protein may be an early marker to predict risk for severity of COVID-19', *Journal of Medical Virology*, 92(11), pp. 2409–2411. doi:10.1002/jmv.26097.

Angela, K.A.P. and Sumohadi, I.M.D. (2022) 'Hubungan d-dimer Dengan Tingkat Keparahan Infeksi covid-19', Intisari Sains Medis, 13(2), pp. 393–398. doi:10.15562/ism.v13i2.1412.

Cennimo, J.D. (2023) *Coronavirus disease 2019 (covid-19)*, *Practice Essentials, Background, Route of Transmission*. Available at: https://emedicine.medscape.com/article/2500114-overview?form=fpf (Accessed: 29 June 2023).

Chen, X. et al. (2020) 'Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 level in critically ill patients with coronavirus disease 2019', Clinical Infectious Diseases, 71(8), pp. 1937–1942. doi:10.1093/cid/ciaa449.

Clinical spectrum (no date) *National Institutes of Health*. Available at: https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/ (Accessed: 29 June 2023).

Dahan, S. *et al.* (2020) 'Ferritin as a Marker of Severity in COVID-19 Patients: A Fatal Correlation', *The Israel Medical Association journal : IMAJ*, 22(8), pp. 494–500. doi:33236582.

Dai, M. *et al.* (2020) 'Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak,' Cancer Discovery, 10(6), pp. 783–791. doi:10.1158/2159-8290.cd-20-0422.

Data Perkembangan Terkait Kasus Covid-19 (Corona) di kota Yogyakarta per Hari hingga 30 Oktober 2023 (no date) *Tabel Virus Korona di Kota Yogyakarta 30 Oktober 2023: 50.665 kasus, 572 meninggal | per tanggal - Hari Ini | urut Tanggal | Andra Farm*. Available at: https://m.andrafarm.com/_andra.php?_i=daftar-co19-kota&noneg=39-5&urut=1&asc=01100000000 (Accessed: 25 June 2023).

Farshbafnadi, M. *et al.* (2021) 'Aging & covid-19 susceptibility, disease severity, and clinical outcomes: The role of entangled risk factors', *Experimental Gerontology*, 154, p. 111507. doi:10.1016/j.exger.2021.111507.

Giamarellos-Bourboulis, E.J. *et al.* (2022) 'Development and validation of SCOPE SCORE: A clinical score to predict COVID-19 pneumonia progression to severe respiratory failure', *Cell Reports Medicine*, 3(3), p. 100560. doi:10.1016/j.xcrm.2022.100560.

Gęca, T. *et al.* (2022) 'Increased risk of COVID-19 in patients with diabetes mellitus—current challenges in pathophysiology, treatment and prevention', *International Journal of Environmental Research and Public Health*, 19(11), p. 6555. doi:10.3390/ijerph19116555.

Haam, J.H. *et al.* (2023) 'Diagnosis of obesity: 2022 update of Clinical Practice Guidelines for obesity by the Korean Society for the study of Obesity', *Journal of Obesity & Metabolic Syndrome*, 32(2), pp. 121–129. doi:10.7570/jomes23031.

Hafez, W. *et al.* (2023) 'Interleukin-6 and the determinants of severe covid-19: A retrospective cohort study', Medicine, 102(45). doi:10.1097/md.0000000000036037.

He, Y. *et al.* (2022) 'Association between smoking and covid-19 severity: A multicentre retrospective observational study', *Medicine*, 101(29). doi:10.1097/md.0000000000029438.

Hu, B. *et al.* (2020) 'Characteristics of SARS-COV-2 and COVID-19', *Nature Reviews Microbiology*, 19(3), pp. 141–154. doi:10.1038/s41579-020-00459-7.

Indonesia: Who coronavirus disease (covid-19) dashboard with vaccination data (no date) *World Health Organization*. Available at: https://covid19.who.int/region/searo/country/id (Accessed: 25 June 2023).

Jin, J.-M. *et al.* (2020) 'Gender differences in patients with COVID-19: Focus on severity and mortality', *Frontiers in Public Health*, *8*. doi:10.3389/fpubh.2020.00152.

Kalligeros, M. *et al.* (2020) 'Association of Obesity with Disease Severity Among Patients with Coronavirus Disease 2019,' Obesity, 28(7), pp. 1200–1204. doi:10.1002/oby.22859.

Klein, I.A. *et al.* (2021) 'Impact of cancer history on outcomes among hospitalized patients with COVID-19', *The Oncologist*, 26(8), pp. 685–693. doi:10.1002/onco.13794.

Koh, W.C. *et al.* (2020) 'What do we know about SARS-CoV-2 transmission? A systematic review and meta-analysis of the secondary attack rate and associated risk factors,' PLoS ONE, 15(10), p. e0240205. doi:10.1371/journal.pone.0240205.

Kotla, N.K. *et al.* (2022) 'The role of ferritin in health and disease: Recent advances and understandings', *Metabolites*, 12(7), p. 609. doi:10.3390/metabo12070609.

Kuderer, N.M. *et al.* (2020) 'Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study,' The Lancet, 395(10241), pp. 1907–1918. doi:10.1016/s0140-6736(20)31187-9.

Lamers, M.M. and Haagmans, B.L. (2022) 'SARS-COV-2 pathogenesis', *Nature Reviews Microbiology*, 20(5), pp. 270–284. doi:10.1038/s41579-022-00713-0.

McArthur, L. *et al.* (2020) 'Review of burden, clinical definitions, and management of covid-19 cases', *The American Journal of Tropical Medicine and Hygiene*, 103(2), pp. 625–638. doi:10.4269/ajtmh.20-0564.

Mubarak, R. *et al.* (2021) 'D-dimer analysis in COVID-19 patients', *INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY*, 28(1), pp. 5–9. doi:10.24293/ijcpml.v28i1.1812.

Parolina, L. *et al.* (2022) 'Clinical characteristics of COVID-19 in patients with tuberculosis and factors associated with the disease severity', *International Journal of Infectious Diseases*, 124. doi:10.1016/j.ijid.2022.04.041.

Pascarella, G. *et al.* (2020) 'Covid-19 diagnosis and management: A comprehensive review', *Journal of Internal Medicine*, 288(2), pp. 192–206. doi:10.1111/joim.13091.

Peng, K. *et al.* (2023) 'Risk of autoimmune diseases following COVID-19 and the potential protective effect from vaccination: A population-based Cohort Study', *eClinicalMedicine*, 63, p. 102154. doi:10.1016/j.eclinm.2023.102154.

Peng, M. *et al.* (2021) 'Role of hypertension on the severity of COVID-19: A Review', *Journal of Cardiovascular Pharmacology*, 78(5). doi:10.1097/fjc.0000000000001116.

Popkin, B.M. *et a*l. (2020) 'Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships,' Obesity Reviews, 21(11). doi:1111/obr.13128.

Robilotti, E.V. *et al.* (2020) 'Determinants of covid-19 disease severity in patients with cancer', *Nature Medicine*, 26(8), pp. 1218–1223. doi:10.1038/s41591-020-0979-0.

Sabaka, P. *et al.* (2021b) 'Role of interleukin 6 as a predictive factor for a severe course of covid-19: Retrospective data analysis of patients from a long-term care facility during covid-19 Outbreak', *BMC Infectious Diseases*, 21(1). doi:10.1186/s12879-021-05945-8.

Sadeghi-Haddad-Zavareh, M. *et al.* (2021) 'C-reactive protein as a prognostic indicator in COVID-19 patients', *Interdisciplinary Perspectives on Infectious Diseases*, 2021, pp. 1–5. doi:10.1155/2021/5557582.

Sama, I.E. et al. (2020) 'Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin–angiotensin–aldosterone inhibitors', European Heart Journal, 41(19), pp. 1810–1817. doi:10.1093/eurheartj/ehaa373.

Sari, E.P., Medison, I. and Russilawati, R. (2022) 'Association between Ferritin Levels and Severity of COVID-19 in RSUP dr. M. Djamil Padang', Jurnal Respirologi Indonesia, 42(3), pp. 237–243. doi:10.36497/jri.v42i3.244.

Sattar, N. and Valabhji, J. (2021) 'Obesity as a risk factor for severe COVID-19: Summary of the best evidence and implications for Health Care', *Current Obesity Reports*, 10(3), pp. 282–289. doi:10.1007/s13679-021-00448-8.

Sun, J. *et al.* (2021) *Covid-19 disease severity among people with HIV infection or solid organ transplant in the United States: A nationally-representative, Multicenter, observational cohort study* [Preprint]. doi:10.1101/2021.07.26.21261028.

Symptoms of COVID-19 (no date) *Centers for Disease Control and Prevention*. Available at: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html (Accessed: 25 June 2023).

Ueyama, H. *et al.* (2020) 'Gender difference is associated with severity of coronavirus disease 2019 infection: An Insight from a meta-analysis', *Critical Care Explorations*, 2(6). doi:10.1097/cce.0000000000000148.

Walandow, K.J., Marunduh, S.R. and Engka, J.N.A. (2022) 'Perbandingan Kadar D-dimer pada Pasien COVID-19 Bergejala Sedang dan Berat', eBiomedik, 10(1), pp. 29–34. doi:10.35790/ebm.v10.i1.37914.

What is coronavirus? (2022) *Johns Hopkins Medicine*. Available at: https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus (Accessed: 25 June 2023).

Yao, Y. *et al.* (2020) 'D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: A case control study', *Journal of Intensive Care*, 8(1). doi:10.1186/s40560-020-00466-z.

Zhang, J. et al. (2020) 'Clinical characteristics of 140 patients infected with SARS-COV-2 in Wuhan, China', Allergy, 75(7), pp. 1730–1741. doi:10.1111/all.14238.